Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GALR2 | O43603 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824874 | 0.84 | SMN1; SMN2 (0.50) | POLBLMNAGALR2SMN1; SMN2TSHR | |
| SCHEMBL6634074 | 0.82 | ALDH1A1 (0.57) | POLBLMNAGALR2SMN1; SMN2GPR35 | |
| SCHEMBL30807120 | 0.82 | ALDH1A1 (0.57) | POLBLMNAGALR2SMN1; SMN2GPR35 | |
| SCHEMBL16302885 | 0.81 | SMN1; SMN2 (0.48) | POLBLMNAGALR2SMN1; SMN2TSHR | |
| SCHEMBL15426466 | 0.81 | SMN1; SMN2 (0.59) | LMNASMN1; SMN2TSHRCYP3A4GPR35 | |
| SCHEMBL14748024 | 0.81 | POLB (0.50) | POLBLMNAGALR2SMN1; SMN2PKM | |
| SCHEMBL790395 | 0.81 | POLB (0.50) | POLBLMNAGALR2SMN1; SMN2PKM | |
| SCHEMBL6832051 | 0.81 | POLB (0.50) | POLBLMNAGALR2SMN1; SMN2TSHR | |
| SCHEMBL28897809 | 0.78 | POLB (0.47) | POLBLMNAGALR2SMN1; SMN2PKM | |
| SCHEMBL15828585 | 0.78 | LMNA (0.47) | POLBLMNAGALR2SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-9278983-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8853238-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | NR4A1, NR2C2, NR0B1 | POLB 4715/4885LMNA 1591/4885GALR2 584/4885 |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | POLB 4724/4885LMNA 1456/4885GALR2 498/4885 |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | NR4A1, NR2C2, NR0B1 | POLB 4737/4885LMNA 1629/4885GALR2 667/4885 |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, CRH | POLB 4563/4885LMNA 4449/4885GALR2 180/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | POLB 4724/4885LMNA 1456/4885GALR2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.